Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis

Table 1

Demographic characteristics at baseline.

Baseline characteristics	Teriflunomide	Glatiramer acetate	value
Patients	29	30
Mean age, years (SD)	57.9 (7.6)	52.4 (11.3)	0.03
Median age (years)	59.3	55.8
Female % ()	58.6 (17)	66.7 (20)	0.71
SPMS % ()	96.6 (28)	86.7 (26)
Mean disease duration, years (SD)	16.7 (9.5)	15.1 (10.4)	0.54
Median disease duration (years)	14.4	12.6
Mean treatment duration, months (SD)	32.4 (13.6)	46.9 (43.9)	0.09
Median treatment duration, months (SD)	32.9	34.2
EDSS mean (SD)	5.9 (1.3)	5.7 (1.6)	0.58
EDSS median	6	6
T25FW mean, seconds (SD)	10.3 (5.7)	15.3 (13.6)	0.11
T25FW median, seconds	8.1	11.6

SPMS: secondary progressive multiple sclerosis; EDSS: expanded disability status scale; T25FW: timed 25-foot walk; SD: standard deviation; : number of subjects.